Drug intelligence / Profile preview

MAY-66

Development stage: Discontinued
Lead developer: Mayfield Pharmaceuticals
Modality: Small Molecules
Administration: Vaginal

Overview

MAY-66 is a proprietary pharmaceutical formulation of a well-known anti-infective agent, currently in development for the treatment of recurrent bacterial vaginosis (BV). Developed by Mayfield Pharmaceuticals, a subsidiary of Harrow (formerly Harrow Health), the drug is designed to address the high recurrence rates associated with standard BV treatments. While the specific active ingredient has not been publicly disclosed in detail, the formulation is intended to optimize delivery and efficacy for vaginal health. Mayfield was established as a spin-out to focus on unmet needs in women's health, with MAY-66 as its lead candidate. The project has received investment from Solas BioVentures to support its early-stage development and clinical progression.

Beyond the preview

Go deeper on MAY-66.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAY-66.

Explore the full profile